Understanding the evolving CAR-T market

In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy.

Four predictions on the future of personalised medicine

For as long as there have been people, there have been illness and disease to hobble them.

Demonstrating the value of RWE

A new cross-industry effort hopes to research the benefits of RWE and promote acceptance of alternatives to traditional trials.

Q&A: Draper’s Jenna Balestrini on the future of CAR-T

As exciting as CAR-T is, there are still myriad challenges preventing it from reaching its full potential.

Seattle Genetics plans to file breast cancer drug tucatinib

Seattle Genetics has announced plans to file its breast cancer drug tucatinib after the drug met targets in a heavily pre-treated group of patients with advanced disease.

AZ’s new cancer drugs drive another stellar quarter